FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...

Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseResults show, for the ...

Follow ZDNET: Add us as a preferred source on Google. Have a USB device near you? Look closely at the port -- do you see a color? It turns out that it actually means something. There's a standardized ...